Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

STOCK INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) and Encourages Long-Term Investors to Contact the Firm

Newsfile 7 days ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) and Encourages Long-Term Investors to Contact the Firm for Additional Information

Newsfile April 2, 2024

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

GlobeNewswire March 14, 2024

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

GlobeNewswire March 4, 2024

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

GlobeNewswire February 29, 2024

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

GlobeNewswire February 16, 2024

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

GlobeNewswire December 13, 2023

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

GlobeNewswire November 13, 2023

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

GlobeNewswire October 31, 2023

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

GlobeNewswire October 18, 2023

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

GlobeNewswire October 17, 2023

Y-mAbs Announces Publication in Cancers

GlobeNewswire October 16, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)

PR Newswire September 21, 2023

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

GlobeNewswire September 21, 2023

Y-mAbs to Participate at Upcoming Investor Conferences in September

GlobeNewswire September 6, 2023

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

GlobeNewswire August 10, 2023

Y-mAbs to Participate at Upcoming Investor Conferences

GlobeNewswire August 2, 2023

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

GlobeNewswire August 1, 2023

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

GlobeNewswire May 26, 2023